The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

In this study, hypoxia was found to selectively enhance lipopolysaccharide (LPS)-induced interleukin (IL)-13 and IL-33 expression in mast cells via hypoxia-inducible factor (HIF)-1α. The increase in ...

The signature lesion in ccRCC is inactivation of the VHL tumor suppressor gene and consequent upregulation of the HIF transcription factor. An earlier case report described a ccRCC patient who was ...

Results We showed that hypoxia enhanced the stemness of HCC cells and hepatocarcinogenesis through enhancing HIF-1α deSUMOylation by SENP1 and increasing stabilisation and transcriptional activity of ...

Westen Blot results showed that GSP can accelerate DU wound healing via AKT1/HIF-1α/VEGF axis. Conclusion: GSP target binding to AKT1 accelerates DU wound healing via the regulation of HIF-1α/VEGF ...

1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

It has been developed to target both the PD-1 and VEGF blockade in cancers and has proven itself in the clinic to do well in targeting patients with NSCLC. Especially, considering the fact that ...

targeting PD-L1 and VEGF with SYN-2510, aiming to capitalize on promising immunotherapy trends. SYN-2510 shows early clinical promise in solid tumors, with plans for phase 3 trials in NSCLC and ...

Zongertinib is under FDA priority review for HER2-mutant advanced NSCLC, showing promise as a groundbreaking oral therapy. The phase 1b BEAMION LUNG-1 trial reported a 71% objective response rate and ...

Small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) are the two main types of lung cancer. Most lung cancers are NSCLC. Only about 15% of lung cancers are SCLC. Their names stem ...